

Aziza El Harchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8774554/publications.pdf>

Version: 2024-02-01

26
papers

896
citations

567281

15
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

1106
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological activation of the hERG K ⁺ channel for the management of the long QT syndrome: A review. <i>Journal of Arrhythmia</i> , 2022, 38, 554-569.	1.2	7
2	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 85.	2.4	17
3	The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine. <i>Physiological Reports</i> , 2020, 8, e14385.	1.7	4
4	Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide. <i>Bioorganic Chemistry</i> , 2020, 98, 103717.	4.1	2
5	Investigation of hERG1b Influence on hERG Channel Pharmacology at Physiological Temperature. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2018, 9, 92-103.	0.4	10
6	In silico investigation of a KCNQ1 mutation associated with short QT syndrome. <i>Scientific Reports</i> , 2017, 7, 8469.	3.3	44
7	Atrial arrhythmogenicity of KCNJ2 mutations in short QT syndrome: Insights from virtual human atria. <i>PLoS Computational Biology</i> , 2017, 13, e1005593.	3.2	51
8	Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking. <i>Biochemical Pharmacology</i> , 2016, 113, 24-35.	4.4	34
9	Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 86, 42-53.	1.9	55
10	hERG potassium channel inhibition by ivabradine requires channel gating. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 87, 126-128.	1.9	2
11	A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 71-72.	1.8	1
12	Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration. <i>Physiological Reports</i> , 2014, 2, e12165.	1.7	8
13	Ranolazine inhibition of hERG potassium channels: Drug-pore interactions and reduced potency against inactivation mutants. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 74, 220-230.	1.9	50
14	Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition. <i>Physiological Reports</i> , 2013, 1, e00175.	1.7	21
15	Proarrhythmia in KCNJ2-linked short QT syndrome: insights from modelling. <i>Cardiovascular Research</i> , 2012, 94, 66-76.	3.8	49
16	Molecular determinants of hERG potassium channel inhibition by disopyramide. <i>Journal of Molecular and Cellular Cardiology</i> , 2012, 52, 185-195.	1.9	30
17	Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K ⁺ Channel. <i>PLoS ONE</i> , 2012, 7, e52451.	2.5	23
18	Early ion-channel remodeling and arrhythmias precede hypertrophy in a mouse model of complete atrioventricular block. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 713-721.	1.9	17

#	ARTICLE	IF	CITATIONS
19	Acidosis Impairs the Protective Role of hERG K ⁺ Channels Against Premature Stimulation. Journal of Cardiovascular Electrophysiology, 2010, 21, 1160-1169.	1.7	30
20	Rabbit, a relevant model for the study of cardiac β_3 -adrenoceptors. Experimental Physiology, 2009, 94, 400-411.	2.0	24
21	Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome. Journal of Molecular and Cellular Cardiology, 2009, 47, 743-747.	1.9	38
22	Transfer of Rolf S3-S4 Linker to hERG Eliminates Activation Gating but Spares Inactivation. Biophysical Journal, 2009, 97, 1323-1334.	0.5	7
23	The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, 119, 118-132.		265
24	I Ks response to protein kinase A-dependent KCNQ1 phosphorylation requires direct interaction with microtubules. Cardiovascular Research, 2008, 79, 427-435.	3.8	47
25	Expression of human ERG K channels in the mouse heart exerts anti-arrhythmic activity. Cardiovascular Research, 2005, 65, 128-137.	3.8	19
26	Long-Term Amiodarone Administration Remodels Expression of Ion Channel Transcripts in the Mouse Heart. Circulation, 2004, 110, 3028-3035.	1.6	41